Advs. Daniel Green and Eli Greenbaum represented Oramed Pharmaceuticals, an Israeli clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, in a licensing transaction with Hefei Tianhui Incubator of Technologies Co., Ltd., of China. The agreement is worth $38 million, with future royalties, and gives HTIT exclusive rights to market Oramed’s oral insulin capsule, in China, Hong Kong and Macau. This deal is alongside a $12 million equity investment in the company.
Advs. Daniel Green and Eli Greenbaum represented Oramed Pharmaceuticals, an Israeli clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, in a licensing transaction with Hefei Tianhui Incubator of Technologies Co., Ltd., of China. The agreement is worth $38 million, with future royalties, and gives HTIT exclusive rights to market Oramed’s oral insulin capsule, in China, Hong Kong and Macau. This deal is alongside a $12 million equity investment in the company.